| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
SCIENTURE HOLDINGS, INC. ( SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that on October 3, 2025, it entered into an agreement (the "Agreement") with Arena Finance Markets, LP and Arena Special Opportunities III LP (together, the "Arena Investors") to fully discharge all outstanding balances on the secured convertible debentures (the "Debentures") previously issued to the Arena Investors by the Company.
Under the terms of the Agreement, the Company and the Arena Investors agreed to amend Section 4(b) of the Debentures to revise the conversion price to $2.4861 per share of common stock. In connection with this amendment, the Arena Investors have agreed to convert the remaining amounts owed under the Debentures into shares of the Company's common stock.
Following the full repayment and conversion and without any further action required by the parties, all obligations under the Debentures and related transaction documents have been deemed paid in full and discharged, except for limited surviving obligations under previously disclosed agreements. In addition, the Debentures and associated transaction documents have been terminated, and all liens, pledges, and security interests previously granted to the Arena Investors as collateral will be automatically and irrevocably released. The Arena Investors have no further funding obligations or credit commitments to the Company.
Posted In: SCNX
